Back to News

CSL Behring joins IQ Consortium

CSL Behring joins IQ Consortium

June 7, 2022


The IQ Consortium is excited to welcome CSL Behring to its membership. 

CSL Behring is a leading global biotech company driven by its promise to save and improve lives by manufacturing plasma-derived and recombinant therapeutic products for serious and rare diseases.

CSL Behring will be represented on the IQ Board of Directors by Silpa Nuthalapati and Jason Newman.